Olanzapine for Chemotherapy-Induced Nausea and Vomiting

Mechanism of Action and Efficacy

• Olanzapine is an atypical antipsychotic with unique antiemetic properties due to its ability to antagonize multiple receptors involved in CINV pathways, including dopaminergic, serotonergic, adrenergic, histaminergic, and muscarinic receptors, as recommended by the National Comprehensive Cancer Network (NCCN) 1, 2, 3
• The NCCN guidelines recommend a 4-drug regimen including olanzapine as a first-line option for highly emetogenic chemotherapy (HEC), which includes olanzapine, an NK1 receptor antagonist, a 5-HT3 receptor antagonist, and dexamethasone 1, 4
• A phase III randomized trial demonstrated that adding olanzapine to standard antiemetic prophylaxis significantly improved complete response rates and no nausea rates during acute, delayed, and overall phases, with a strength of evidence considered high by the NCCN 1
• The American Society of Clinical Oncology (ASCO) and the Multinational Association of Supportive Care in Cancer (MASCC) have also acknowledged the efficacy of olanzapine in preventing CINV, although with some caution regarding its use as a standard antiemetic prophylaxis 5
• Olanzapine has been shown to be effective in preventing CINV in patients receiving highly emetogenic chemotherapy, with a complete response rate of 86% vs 65% compared to standard antiemetic prophylaxis, and a no nausea rate of 74% vs 45% 1
• The European Society for Medical Oncology (ESMO) also recommends olanzapine as an option for preventing CINV in patients receiving highly emetogenic chemotherapy, although with careful consideration of potential side effects and drug interactions 2, 3

Safety and Side Effects

• Common side effects of olanzapine include somnolence, postural hypotension, constipation, dizziness, fatigue, and dyspepsia, as reported by the NCCN and other guideline societies 1, 2
• Important safety considerations include use with caution in elderly patients due to increased mortality in elderly patients with dementia-related psychosis, and avoidance of concurrent use with other dopamine blockers to prevent excessive dopamine blockade, as recommended by the NCCN and the FDA 1
• Rare but serious skin reactions, such as DRESS syndrome, have been reported with olanzapine use, highlighting the need for careful monitoring and patient selection 1

Clinical Pearls and Caveats

• Olanzapine is used "off-label" for CINV, and its use should be carefully considered in patients with certain comorbidities or potential drug interactions, as recommended by the NCCN and other guideline societies 1, 5
• Patient selection is crucial when considering olanzapine, taking into account age, comorbidities, and potential drug interactions, with careful consideration of the strength of evidence supporting its use in different patient populations 1, 5

Olanzapine as an Antiemetic: Indications and Dosage

Chemotherapy-Induced Nausea and Vomiting (CINV)

• The American Society of Clinical Oncology (ASCO) guidelines recommend a 4-medication combination including NK1 receptor antagonist, 5-HT3 receptor antagonist, dexamethasone, and olanzapine for adults with high-emetic-risk chemotherapy (strong recommendation, high-quality evidence) 6, 7
• Olanzapine should be continued on days 2-4 after chemotherapy 6
• For breakthrough nausea and vomiting despite prophylaxis, the National Comprehensive Cancer Network (NCCN) and ASCO recommend olanzapine 5-10 mg daily (category 1) 8, 9
• In a study of 108 patients, olanzapine was superior to metoclopramide: 70% vs. 31% without vomiting (P < 0.01) and 68% vs. 23% without nausea (P < 0.01) 8

Radiation-Induced Nausea and Vomiting

• There is no guideline recommendation for olanzapine in radiation-induced nausea and vomiting 8, 7
• The ASCO 2017 guidelines recommend a 2-medication combination of 5-HT3 receptor antagonist and dexamethasone for high-emetic-risk radiation therapy 8

Dosage Recommendations

• The standard dose for chemotherapy-induced nausea and vomiting is 10 mg orally daily at bedtime on days 1-4 6, 9
• For breakthrough nausea and vomiting, 5-10 mg orally daily is recommended 9

Rationale for Combining Olanzapine and Ondansetron in Severe Vomiting

Primary Mechanism and Synergistic Effect

• Olanzapine provides broad-spectrum receptor antagonism across multiple pathways including dopaminergic, serotonergic, adrenergic, histaminergic, and muscarinic receptors, addressing nausea pathways that ondansetron alone cannot adequately suppress, particularly those mediated by dopamine and histamine 10
• This multi-receptor blockade by olanzapine addresses nausea pathways that ondansetron alone cannot adequately suppress, particularly those mediated by dopamine and histamine 10

Evidence-Based Efficacy

Guideline Support for Combination Therapy

• The American Society of Clinical Oncology (ASCO) guidelines recommend a 4-drug regimen including olanzapine, a 5-HT3 antagonist (such as ondansetron), an NK1 receptor antagonist, and dexamethasone for highly emetogenic chemotherapy as first-line prophylaxis (strong recommendation, high-quality evidence) 11, 12, 13
• When olanzapine 5 mg was added to standard antiemetic prophylaxis (5-HT3 antagonist, dexamethasone, and NK1 antagonist), delayed-phase complete response improved from 66% to 79% (P < 0.0001) in a phase III trial of 710 adults receiving cisplatin-based chemotherapy 11, 12

Critical Safety Considerations

Olanzapine-Specific Warnings

• The most common side effect of olanzapine is somnolence (35% in chemotherapy studies), which may be beneficial for nighttime dosing but requires patient counseling 10
• Olanzapine does not inhibit or induce CYP3A4, avoiding the need for dexamethasone dose adjustments 10

Drug Interaction Considerations

• Both olanzapine and ondansetron can contribute to sedation; patients should be counseled about driving and operating machinery 10

When Combination Fails

• Considering scopolamine transdermal patch or cannabinoids for refractory cases may be an option 14

Olanzapine for Chemotherapy‑Induced Nausea and Vomiting in Breast Cancer Patients

Indication & Prophylactic Dosing

• Olanzapine 10 mg orally at bedtime on days 1‑4 should be added to a 4‑drug anti‑emetic regimen (NK1‑receptor antagonist, 5‑HT₃‑receptor antagonist, dexamethasone, and olanzapine) for women receiving highly emetogenic chemotherapy, including anthracycline‑cyclophosphamide (AC) protocols. (high‑quality Phase III evidence; strong recommendation) 15, 16, 17
• For AC regimens, olanzapine is continued on days 2‑4 while dexamethasone is given only on day 1. 15, 17

Efficacy Evidence (Phase III Trials)

• In patients treated with highly emetogenic chemotherapy (cisplatin or AC), 74 % achieved “no nausea” with olanzapine versus 45 % without it; complete response (no vomiting and no rescue medication) was 86 % versus 65 %. (Phase III, high‑quality evidence) 17

Management of Breakthrough Nausea/Emesis

• If breakthrough nausea occurs in patients who did not receive prophylactic olanzapine, add olanzapine 5‑10 mg daily to the standard anti‑emetic regimen. 15, 18
• In a study of 108 patients, olanzapine outperformed metoclopramide: 70 % vs 31 % remained vomit‑free and 68 % vs 23 % remained nausea‑free (p < 0.01 for both); no grade 3‑4 adverse events were observed. (Phase III, high‑quality evidence) 15, 18

Clinical Implementation Algorithm (ASCO‑endorsed)

Day 1 of Chemotherapy (AC or other highly emetogenic regimens)

Days 2‑4

• Olanzapine 10 mg PO at bedtime continues for all highly emetogenic regimens. 15, 17
• For cisplatin‑based or other non‑AC regimens, dexamethasone is continued; for AC regimens dexamethasone is omitted on days 2‑4. 15, 17

Breakthrough Nausea Despite Prophylaxis

• If olanzapine was not given prophylactically, add olanzapine 5‑10 mg daily. 15, 18
• If olanzapine has already been used, consider switching to a drug from another class (e.g., additional NK1 antagonist, benzodiazepine, or cannabinoid). 15, 18

Radiation‑Induced Nausea (ASCO Guidance)

• ASCO guidelines do not recommend olanzapine for radiation‑induced nausea and vomiting; for highly emetogenic radiation therapy, a 5‑HT₃ antagonist combined with dexamethasone is advised. 15

All statements are derived from peer‑reviewed Phase III trials published in 2017 and reflect the recommendations of the American Society of Clinical Oncology (ASCO).

Olanzapine 10 mg as a Category 1 Antiemetic for Highly Emetogenic Chemotherapy

Guideline Recommendation

• The National Comprehensive Cancer Network (NCCN) classifies olanzapine‑containing antiemetic regimens as Category 1 recommendations for patients receiving highly emetogenic chemotherapy, indicating the highest level of evidence and consensus. [19][20]21

Standard Prophylactic Regimen (Day 1 – Day 4)

• Day 1: Administer olanzapine 10 mg orally once, palonosetron 0.25 mg intravenously once, and dexamethasone 20 mg intravenously once as part of the initial antiemetic prophylaxis. 19
• Days 2–4: Continue olanzapine 10 mg orally once daily to maintain antiemetic coverage throughout the delayed phase. 19

Dose Adjustments for Special Populations

• Standard adult dose: 10 mg of olanzapine taken daily in the prophylactic regimen. 19
• Elderly or patients experiencing excessive sedation: Reduce to 5 mg of olanzapine daily, which maintains efficacy while lowering the risk of somnolence. [20][21]

Management of Breakthrough Nausea

• For breakthrough nausea or vomiting despite prophylaxis, the NCCN recommends a rescue dose of olanzapine 5–10 mg daily. This dose range has been shown to be effective in clinical practice. 22